• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
ACCESS Newswire Inc. Common Stock
Amphastar Pharmaceuticals, Inc. - Common Stock
Computershare Ltd AUD
Fansunite Entertainment Inc
Happen, Inc. - Common Stock
Maui Land & Pineapple Company, Inc. Common Stock
Oceanic Iron Ore Corp New
Spectra7 Microsystems Inc
TOP Ships Inc. - Common Stock
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics, Inc. - Common Stock (NQ:CYTH)

0.7206 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
March 26, 2025
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the... 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
March 13, 2025
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
February 20, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
February 07, 2025
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
January 14, 2025
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, FLIC, ARCH, CYTH on Behalf of Shareholders
December 16, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARCH, CYTH on Behalf of Shareholders
December 14, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
December 11, 2024
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders
December 10, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, CYTH, ARCH on Behalf of Shareholders
December 05, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 14, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
November 06, 2024
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
October 21, 2024
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
From Pacira BioSciences
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
September 06, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
September 05, 2024
From Cyclo Therapeutics
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
August 27, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
August 27, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
August 26, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders
August 24, 2024
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
August 22, 2024
From Halper Sadeh LLC
Via Business Wire
News headline image
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
August 22, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
August 22, 2024
From Rafael Holdings, Inc.; Cyclo Therapeutics
Via GlobeNewswire
News headline image
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 15, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
July 29, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
June 25, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
June 14, 2024
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
May 30, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 18, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
News headline image
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
March 14, 2024
From Cyclo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap